• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1990 Fiscal Year Final Research Report Summary

Developmental Studies of Nucleosidic Anti-RNA Virus Drugs

Research Project

Project/Area Number 01870091
Research Category

Grant-in-Aid for Developmental Scientific Research (B).

Allocation TypeSingle-year Grants
Research Field Chemical pharmacy
Research InstitutionHokkaido University

Principal Investigator

MATSUDA Akira  Hokkaido University, Faculty of Phrmaceutical Sciences Associate Professor, 薬学部, 助教授 (90157313)

Co-Investigator(Kenkyū-buntansha) MINAKAWA Noriaki  Hokkaido University, Faculty of Phrmaceutical Sciences Associate Professor, 薬学部, 教務職員 (40209820)
Project Period (FY) 1989 – 1990
KeywordsRNA-virus / Chemotherapy / Nucleoside / Antimetabolite / 5-ethynyl-1-beta-D-ribo-furanosylimidazole-4 / Ribavirin / 3-Deazaaristeromycin
Research Abstract

The only antiviral drugs which have been licensed for the treatment of respiratory virus infections are amantadine (rimantadine) in the prophylaxis or early therapy of influenza A virus infection and ribavirin in the therapy, by aerosol, of severe respiratory syncytial virus (RSV) infections in children. Ribavirin was described almost two decades ago as a broad-spectrum antiviral agent. It has shown clinical efficacy against influenza A and B virus, RSV, parainfluenza virus infections and Lassa fever. In the treatment of orthomyxo-and paramyxovirus infections, and in particular, RSV infections in children, ribavirin can be administered as a small-particle aerosol.
We have designed a new series of imidazole derivatives, namely, 5-alkynyl-1-beta-D-ribofuranosylimdazole-4-carboxamides, which can be viewed as close analogs of ribavirin, whereby the N at position 2 of the triazole ring is replaced by a alkynyl-carbon moiety. 5-Ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) is … More the prototype of this class of compounds.
The 5-alkynyl-1-beta-D-ribofuranosylimidazole-4-carboxamides were synthesized by Pd-catalyzed cross-coupling reaction of terminal alkynes with with 5-iodo derivatieves, which was easily obtained from AICAR in several steps. Other 5-alkyl and derivatives were also synthesized from the corresponding 5-alkynyl derivatives. Among these, EICAR showed the most potent antiviral activity against poxviruses (vaccinia), togaviruses (Sindbis and Semliki forest), arenaviruses (Junin and Tacaribe), reoviruses (type I), orthomyxoviruses (influenza A and B), and paramyxoviruses (parainfluenza type 3, measles, SSPE, and RSV). Although the antiviral activity spectrum of EICAR is similar to that of ribavirin, the potency by EICAR was about 10-to 100-fold greater than that of ribavirin. In vivo antivaccinia virus activity of EICAR was also examined. When administered daily at a dose of either 10 or 25mg/kg, EICAR effected a significant reduction in the number of vaccinia virus tail lesions, without apparent toxicity for the host. Less

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] N. Minakawa, T. Takeda, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antineoplastic activity of 5ーethynylー1ーβーDーribofuranosylimidazoleー4ーcarboxamide (EICAR) and its derivatives." J. Med. Chem.,. 34. 778-786 (1991)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] N. Minakawa, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antitumor activities of 5ーethynylimidazoleー4ーcarboxamide and ーcarbonitrile derivatives." Nucleosides Nucleotides,. 9. (1990)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] E. De Clercq, M. Cools, J. Balzarini, R. Snoeck, and A. Matsuda: "Antiviral activity of 5ーethynylー1ーβーDーribofuranosylimidazoleー4ーcarboxamide and related compounds." Antimicrob. Agents Chemother.,. 35. (1991)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 松田 彰: "糖部変換ヌクレオシド語導体合成の最近の進歩" 有機合成化学協会誌. 48. 907-920 (1990)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] N. Minakawa, T. Takeda, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antineoplastic activity of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and its derivatives." J. Med. Chem.34. 778-786 (1991)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] N. Minakawa, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antitumor activities of 5-ethynylimidazole-4-carboxamide and -carbonitrile derivatives." Nucleosides Nucleotides. 9. (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] E. De Clercq, M. Cools, J. Balzarini, R. Snoeck, T. Ueda, N. Minakawa, and A. Matsuda: "Antiviral activity of 5-ethynyl-1-beta-D-ribofuranosylimi-dazole-4-carboxamide and related compounds." Antimicrob. Agents Chemother.35. (1991)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] A. Matsuda: "Recent Development of anti-HIV Nucleosides" J. Synthetic Org. Chem., Japan. 48. 907-920 (1990)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1993-08-12  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi